XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
STOCK-BASED COMPENSATION
6 Months Ended
Jun. 30, 2021
Compensation Related Costs [Abstract]  
STOCK-BASED COMPENSATION

NOTE 10 – STOCK-BASED COMPENSATION

 

Options

 

Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding options survived. The below information details the Company’s associated option activity.

 

As of June 30, 2021, options to purchase Common Stock were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). Under the 2017 Plan, up to 2,000,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, up to 7,250,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards.

 

Employees, consultants, and directors are eligible for awards granted under the 2017 and 2015 Plans. The Company registered an additional total of 20,000,000 shares of its Common Stock, which may be issued pursuant to the Registrant’s Amended and Restated 2015 Equity Incentive Plan (the “Plan”). Such additional shares were approved by the shareholders of the Company on August 10, 2020 and as reported to the Securities and Exchange Commission (the “SEC”) vide a Current Report on Form 8-K on August 14, 2020. As such, the total number of shares of the Company’s Common Stock available for issuance under the 2015 plan is 27,250,000. After June 30, 2021, the Company issued 1,257,952 of its common shares in lieu of fully vested restricted stock units and 4,244,809 incentive and non-qualified stock options to purchase its Common Stock to its employees. All these grants had been approved by the Board of Directors of the Company under the 2015 Plan.

 

Since the adoption of the 2015 Plan, no further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms.

 

Compensation based stock option activity for qualified and unqualified stock options are summarized as follows:

 

       Weighted 
For the six months ended June 30, 2021      Average 
   Shares   Exercise Price 
Outstanding at January 1, 2021   3,941,301   $0.78 
Expired or canceled   -    - 
Outstanding at June 30, 2021   3,941,301   $0.78 

 

For the year ended December 31, 2020

 

       Weighted 
       Average 
   Shares   Exercise Price 
Outstanding at January 1, 2020   6,145,044   $0.75 
Expired or canceled   (2,203,743)   0.70 
Outstanding at December 31, 2020   3,941,301   $0.78 

 

The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at June 30, 2021:

            Weighted-     
        Weighted-   Average     
    Outstanding   Average   Exercise   Number 
Exercise prices   Options   Remaining Life   Price   Exercisable 
                  
$0.22    1,750,000    4.84   $0.22    1,750,000 
 0.38    900,000    4.16    0.38    900,000 
 0.73    762,500    3.78    0.73    762,500 
 1.37    150,000    2.00    1.37    150,000 
 1.43    300,000    3.91    1.43    300,000 
 11.88    2,359    0.51    11.88    2,359 
 15.00    75,000    3.91    15.00    75,000 
 19.80    1,442    0.34    19.80    1,442 
      3,941,301    4.28   $0.78    3,941,301 

 

 

The compensation expense attributed to the issuance of the options is recognized as they are vested.

 

The employee stock option plan stock options are generally exercisable for ten years from the grant date and vest over various terms from the grant date to three years.

 

The aggregate intrinsic value totaled $0 and was based on the Company’s closing stock price of $0.22 as of June 30, 2021, which would have been received by the option holders had all option holders exercised their options as of that date. Correspondingly, the aggregate intrinsic value totaled $0 and was based on the Company’s closing stock price of $0.22 as of December 31, 2020, which would have been received by the option holders had all option holders exercised their options as of that date.

 

As of June 30, 2021, there was no future compensation cost as all stock options vested prior to December 31, 2019 and the compensation was fully expensed prior to the Merger. In August 2019, the Company had entered into Employment Agreements and incentive compensation arrangements with each of its executive officers, including Dr. Vuong Trieu, the Chief Executive Officer (“CEO”); Dr. Chulho Park, its prior Chief Technology Officer (“CTO’); and Mr. Amit Shah, the Chief Financial Officer (“CFO”). The incentive stock options and the restricted stock awards approved for the Company’s executive officers were granted and issued after June 30, 2021. The Company issued 1,257,952 of its common shares in lieu of fully vested restricted stock units and 4,244,809 incentive and non-qualified stock options to purchase its Common Stock to its employees, including the awards due to the CEO, CFO, the prior CTO and Saran Saund, the Chief Business Officer of the Company. The Company shall measure the stock-based compensation cost and record such cost in the relevant period.

 

Warrants

 

Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding warrants survived. The below information represents the Company’s associated warrant activity.

 

During the three months ended March 31, 2021, 2,035,000 warrants were issued related to private placement. The fair value of these warrants on issue date amounted to $467,637 with an expected life of 1.5 years, as calculated using Black Scholes valuation model. Further, during the three months ended June 30, 2021, and as disclosed in Note 6 above, the Company issued 20,000,000 warrants were issued related to private placement. The fair value of these warrants on issue date amounted to $2,023,552 with an expected life of 1-2 years, as calculated using Black Scholes valuation model.

 

In February 2020, the Company offered to cancel to all the prior warrants of the warrant holders from the 2018 debt financing and offered to reissue new warrants to such warrant holders. Out of all the warrant holders, holders of 13,750,000 warrants opted to participate in the reissuance during the same period in 2020. The company recognized stock-based compensation of $2.1 million as the fair value of the warrants using a Black Scholes valuation model. No similar expense was recorded for the three months ended March 31, 2021.

 

 

The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, as of June 30, 2021 and December 31, 2020 are summarized as follows:

       Weighted- 
       Average 
   Shares   Exercise Price 
Outstanding at January 1, 2021   18,702,500   $0.20 
Issued during six months ended June 30, 2021   24,035,000    0.20 
Expired or cancelled   -   - 
Outstanding at June 30, 2021   42,737,500   $0.20 

 

 

       Weighted- 
       Average 
For the year ended December 31, 2020  Shares   Exercise Price 
         
Outstanding at January 1, 2020   19,515,787   $0.60 
Issued during the year ended December 31, 2020   17,215,000    0.20 
Expired or cancelled   (18,028,287)   0.63 
Outstanding at December 31, 2020   18,702,500   $0.20 

 

The following table summarizes information about warrants outstanding and exercisable at June 30, 2021:

 

    Outstanding and exercisable 
        Weighted-   Weighted-     
        Average   Average     
    Number   Remaining Life   Exercise   Number 
Exercise Price   Outstanding   in Years   Price   Exercisable 
                  
$0.20    1,487,500    2.08   $0.20    1,487,500 
 0.20    41,250,000    2.15    0.20    41,250,000 
      42,737,500    2.15   $0.20    42,737,500 

 

The Company issued 24,035,000 warrants during the six months ended June 30, 2021, of which 22,000,000 warrants issued during the three months ended June 30, 2021. The Company recorded stock-based compensation of approximately $2.0 million, as fair value of the warrants, using a Black Scholes valuation model using the following input values. The expense attributed to the issuances of the warrants was recognized as they vested/earned. These warrants are exercisable for three to five years from the grant date. All the warrants are currently exercisable.

 

Expected Term  1-2 years 
Expected volatility   94.4130.0%
Risk-free interest rates   0.080.25%
Dividend yields   0.00%

 

The Company issued 13,750,000 warrants issued during the six months ended June 30, 2020 were as recorded stock-based compensation of $2.1 million as the fair value of the warrants using a Black Scholes valuation model using the following input values. The expense attributed to the issuances of the warrants was recognized as they vested/earned. These warrants are exercisable for three to five years from the grant date. All the warrants are currently exercisable.

 

Expected Term  3 years 
Expected volatility   140.5%
Risk-free interest rates   1.40%
Dividend yields   0.00%